Axillary lymph node metastasis is a critical prognostic factor for the pathological staging, prognosis, and guiding systemic therapy in patients with invasive breast cancer [1]. Over the past decades, the management of axillary lymph nodes in breast cancer patients has evolved significantly. Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) as the standard surgical approach, offering similar disease-free survival and overall survival rates with fewer side effec…